CT Children's CLASP Guideline Post-COVID Conditions and COVID-19 Long Haul Management

INTRODUCTION	As of September 2021, the COVID-19 pandemic has infected over 5 million children (of over 33 million infections worldwide), representing over 15% of all COVID-19 cases. This number continues to rise with the delta variant of SARS-CoV-2. Although pediatric hospitalizations and deaths remain relatively low, children may be left with long-lasting, post-acute sequelae from their infection, even if the child was initially asymptomatic. "Post-COVID Conditions" is a term to describe the wide range of physical and mental health consequences that are present for ≥4 weeks after an initial COVID-19 infection, even in children who were initially asymptomatic (<i>CDC, 2021</i>). Post-COVID Conditions are thought to affect 5% to 80% of individuals who have had COVID-19 infection of any severity, but the data is limited on its impact on the pediatric population. Because of the uncertainty surrounding Post-COVID Conditions, including the wide range of presentations, difficulty in assessing potential alternative etiologies, and lack of standardized guidance, a thorough, systematic and multi-disciplinary approach to evaluation and management is warranted.							
	Important note : It is important to distinguish between the care outlined below for Post-COVID Conditions and that of Multisystem Inflammatory Syndrome in Children (MIS-C) , which can appear weeks after a child's initial infection as well. MIS-C can be a medical emergency and the management should not follow this referral guideline. The CDC defines MIS-C as an individual <21 years of age with fever, laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (\geq 2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological) AND no alternative plausible diagnosis;							
	AND positive for current/recent SARS-COV-2 infection (or exposure to suspected/confirmed COVID-19 case within the 4 weeks prior to the onset of symptoms)							
ΙΝΙΤΙΛΙ	INITIAL EVALUATION:							
EVALUATION	PCPs should be mindful of the presence of post-COVID conditions after any documented SARS-CoV-2 infection, even if the child is initially asymptomatic. New or persisting symptoms are present for ≥4 weeks from acute infection (i.e., ≥4 weeks from symptom onset and/or first positive test). Note that patients who present with possible MIS-C should be excluded from this guideline.							
	RELEVANT CLINICAL HISTORT/REVIEW OF STSTEIVIS:							
	<u>Past Medical History</u> :							
	 Confirmation of SARS-CoV-2 infection and date of onset Symptom severity (if any) during acute infection History of thrombosis 							
	 Other physical or mental underlying disease states present that may contribute to presentation <u>Family History:</u> 							
	 Note if any immediate family with inherited thrombophilia (i.e., Factor V Leiden, Prothrombin Gene Mutation, Protein S or Protein C deficiency, Anti-thrombin III deficiency) 							
	Symptoms Associated with Post-COVID Conditions (most common):							
Symptoms present for ≥4 weeks from acute infection (i.e., ≥4 weeks from symptom first positive test)								
	• Overall Wellness:							
	 Post-exertional malaise and/or poor endurance (worsening of symptoms following minor physical/mental exertion, worsening 12-48 hours after activity and lasting for days or even weeks 							
	• Cognitive/Mental:							
	Insomnia/difficulty sleeping or hypersomnia							



- Fatigue (compared to before COVID-19 infection)
- Depression, anxiety, or mood/behavioral changes compared to before COVID-19 infection
- Brain fog, cognitive impairment
 - → Complete Appendix A: Pediatric Cognitive Function Short Form
- Head:
 - Mild-moderate, intermittent headache
 - Seizures
- o ENT:
 - Anosmia (loss of smell)
 - Change or loss of taste
 - Persistent nasal congestion
- Lungs:
 - Intermittent dyspnea
 - Persistent cough
 - Exercise intolerance
 - Chest tightness

• Heart:

- Palpitations and/or tachycardia
- Lightheadedness
- Chest pain
- **GI:**
 - Abdominal pain
 - Diarrhea
 - Constipation
 - Nausea/vomiting or inability to tolerate intake
- **GU:**
 - Difficulty or painful urination
- **MS**:
 - Pain
 - Arthralgia
 - Myalgia
 - Paresthesia, neuropathy
 - Muscle weakness
 - Abnormal movements
- o Skin:
 - Rash or abnormal discoloration
- Endocrine:
 - Menstrual cycle irregularities
 - Significant weight loss or weight gain
- \circ Infectious:
 - Fever without concern for MIS-C
- Heme:
 - Signs of thrombosis or anemia
- Other:
 - Any new symptoms that have persisted for more than 4 weeks after a confirmed SARS-CoV-2 infection



	 <u>Timing of Onset</u>: Confirm timing of initial infection Note persisting or new symptoms that are present ≥4 weeks after initial acute infection (i.e., ≥4 weeks from symptom onset and/or first positive test) that are not easily explained by an alternative etiology 			
	FULL PHYSICAL EXAM: *A full physical examination should be completed by the PCP and should note the following components:			
	 Anthropometrics: Weight, height, BMI Skin: Full skin examination; include any swelling, pigmentation, varicosities, ulcers HEENT: standard examination; include any oral ulcerations Cardiac: include heart sounds, perfusion, liver edge, edema 			
	 Lung: include SpO2, location/presence of abnormalities GI: include presence of hepatoslenomegaly, distention, abnormal bowel sounds GU: standard examination, if needed MS: include joint examination, ROM, pain, edema 			
	 Neuro: include a gross neurological examination Heme: assess for any indication of thrombosis, DVT, PE, or stroke RED FLAGS: Any abnormalities on examination should be further investigated and referred, as appropriate 			
	 URGENT/EMERGENT RED FLAGS: Any symptoms or signs of clinical instability, including, but not limited to: 			
INITIAL PCP	Initial Management by PCP:			
MANAGEMENT	 Establish if the patient needs urgent/emergent referral (see URGENT/EMERGENT RED FLAGS above): Refer patient to emergency care, as appropriate Establish if acute intervention is needed (see RED FLAGS above): Standard clinical management should be initiated by the PCP on a case-by-case basis of patient's presenting signs and symptoms Establish if above signs and symptoms could be due to re-infection with SARS-CoV-2: Although rare, reinfection within 90 days of initial infection could occur Consider symptoms, risk factors/exposures, and discussing case with CT Children's Infectious Diseases providers 			
WHEN TO REFER TO LONG HAUL CLINIC	 All patients with a concern for post-COVID conditions can be referred to CT Children's "Long Haul" Clinic in Infectious Diseases. All referrals are considered routine and will be scheduled in 2-3 weeks. Routine referral to Long Haul Clinic if all of the following criteria met: Documented SARS-CoV-2 infection ≥4 weeks prior New or persisting symptoms listed above are present for ≥4 weeks from acute SARS-CoV-2 infection (i.e. >4 weeks from symptom onset and/or positive test result) 			
	 Abnormal/positive Pediatric Cognitive Screen: Appendix A Defer referral if any of the following criteria are present: Absence of acute SARS-CoV-2 infection 			



	 New or persisting symptoms have been present for <4 weeks (i.e., <4 weeks from symptom onset and/or first positive test result) New or persisting symptoms are easily attributable to alternative, underlying disease process Emergency management if URGENT/EMERGENT RED FLAGS are present. Routine referrals are not clinically appropriate in these instances.
HOW TO REFER	Routine Referral to Department of Infectious Diseases and Immunology via CT Children's One Call Access Center Phone: 833.733.7669 Fax: 833.226.2329 Information to be included with the referral: • Notes from recent visits that document specific Post-COVID Conditions that are present • Growth charts (height, weight, BMI) • Copy of documented laboratory report of SARS-CoV-2 infection (include date of test) • Copy of Pediatric Cognitive Function – Short Form (Appendix A) • Copies of other relevant laboratory studies and imaging studies
WHAT TO EXPECT – PCPs	 What to expect from CT Children's Visit: Initial evaluation by Long Haul Clinic in Infectious Diseases within 2-3 weeks. This may be an inperson or telemedicine visit. Comprehensive history, review of systems and physical exam Confirmation of Long Haul diagnosis by Infectious Diseases provider Baseline laboratory studies Additional laboratory and imaging studies, as indicated Referral to appropriate subspecialists to assess for other organic causes, as appropriate If appropriate, patient will be referred to CT Children's Pain Team to assist with a multi-disciplinary approach for symptomatic management of certain symptoms such as fatigue, brain fog, etc. If Long Haul diagnosis is unlikely to be the etiology of current presentation, patient will be transitioned back to the PCP for further management.
WHAT TO EXPECT – Patients/Families/ Caregivers	 PCPs to review with patients/families/caregivers: Initial evaluation by Long Haul Clinic in Infectious Diseases within 2-3 weeks, to confirm Post-COVID Condition diagnosis. There is no specific cure for Post-COVID Conditions and much is still unknown. Your child will be managed on a case-by-case basis, and resolution of symptoms may take some time. Symptoms may initially be managed by your primary care provider. Your initial visit with the Long Haul Clinic may be in-person or through a telemedicine visit. The provider may order further lab tests and studies, as appropriate. If appropriate, your symptoms may be managed by a multi-disciplinary group of specialists, with further specialty follow up to assess for any other causes of your symptoms. It may take 2-3 weeks to be seen by other specialists after your initial visit with Infectious Diseases. Your specialists will be communicating closely with your primary care provider.



Appendix A: Pediatric Cognitive Function – Short Form

Screening is positive if: score <25 or ≥2 items are "quite/very much".

If patient has baseline ADHD, a significant change from baseline (prior to COVID-19 infection) should prompt a referral.

Neuro-QOL Item Bank v2.0 -Pediatric Cognitive Function - Short Form

Pediatric Cognitive Function – Short Form

Please respond to each question or statement by marking one box per row.

		Not at all	A little bit	Somewhat	Quite a bit	Very much
NGCOGped03	I forget schoolwork that I need to do	5	. □	3	2	
NOCOGped05	I sometimes forget what I was going to say	s S	□ +	□ 3		
NOCOGped08	I react slower than most people my age when I play games.	5	□ .	3		
NQC0Gped15	I forget things easily	5	□ 4	3	2	
NOCOGped17	I have trouble remembering to do things (e.g., school projects)	5	□ +	□ 3		
NQC0Gped18	It is hard for me to concentrate in school	5	□ 4	□ 3		
NQC0Gped19	I have trouble paying attention to the teacher.	5	□ .	□ 3		
NOCOGped20	I have to work really hard to pay attention or I will make a mistake	5	□ .	3		

©2008-2013 David Cella and the PROMIS Health Organization on behalf of the National Institute for Neurological Disorders and Stroke (NINDS). Used with permission.



Key References:

- Children and COVID-19: State-Level Data Report (aap.org)
- Key Points | Evaluating and Caring for Patients with Post-COVID Conditions | CDC
- Tracking Johns Hopkins Coronavirus Resource Center (jhu.edu)

Other References:

- Brackel, C.L.H., Lap, C.R., Buddingh, E.P., et al. Pediatric long-COVID: an overlooked phenomenon?. *Pediatr Pulmonol*. Published online June 8, 2021. doi:<u>10.1002/ppul.25521</u>.
- Buonsenso, D., Munblit, D., De Rose, C., et al. Preliminary evidence on long COVID in children. *Acta Paediatr*. 2021;110(7):2208-2211. doi:10.1111/apa.15870PubMed.
- Ludvigsson, J.F. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. *Acta Paediatr*. 2021;110(3):914-921. doi:<u>10.1111/apa.15673PubMed</u>.
- Say, D., Crawford, N., McNab, S., Wurzel, D., Steer, A., Tosif, S. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. *Lancet Child Adolesc Health*. 2021;5(6):e22-e23. doi:<u>10.1016/S2352-4642(21)00124-3PubMed</u>.

